Genmab — Juli 2022

[Helge_LarsenPI-redaktør]

Der er vist et gammelt modstandsområde i 2630-2640 i følge BSinvest. Det er blevet testet et par gange med afvisning til
følge.

[Riis7]

kunne være fedt med de 3000 i 2022 og høstfest:-) men ja nok os sundt med en lille pause, er os gået hurtigt den sidste tid

[deleted-user]

Man må også konstatere, at signalet fra Saxo bank i 2661 kom relativt tæt på kurstoppen i 2663

[ProinvestorNEWS]

USA/lukning: Aktier steg trods hug til Meta - https://www.proinvestor.com/investornyt/857566/usa-lukning-aktier-steg-trods-hug-til-meta-satser-pa-midelre-fed

[Helge_LarsenPI-redaktør]

Godmorgen.

[Stroka]

God morgen.

[transalp]

Go morgen..

[JKY_VH]

Lad nu solen skinne på Genmab i dag og god morgen;-)

[Riis7]

tror desværre det forsætter med at flytte over i grøn og tech og væk fra def aktier som novo og genmab

[JKY_VH]

Ja, det ser sådan ud pt.

[Riis7]

US dollar falder os tilbage

[E_L]

TIVDAK Q2 $17.2mn, YTD $28.6mn https://investor.seagen.com/press-releases/news-details/2022/Seagen-Reports-Second-Quarter-2022-Financial-Results/default.aspx

[Riis7]

medvind nu:-)

[E_L]

TIVDAK launch progressing well
• Pleased with positive feedback from oncology community
• Well-positioned in 2L/3L setting; area of high unmet need
https://s21.q4cdn.com/327105422/files/doc_financials/2022/q2/revised/SGEN-2Q22-Presentation-28July2022.pdf

[deleted-user]

That will be all net sales and no collaboration rev. Wonder when Genmab will book first sale?

[E_L]

not sure; maybe they'll choose to let Seagen book all US sales, even if driven by Genmab co-promotion? would make accounting easier i would imagine? so we would have to wait for other approvals first , outside US?

[deleted-user]

Could be. I may ask Mr. Winkel at our next QA. The sales force at Genmab is hopefully busy practicing for Epco release. But would be nice to see some numbers to prove they are progressive now and not just pulling their monthly payment

[deleted-user]

I assumed Genmab would co-op in US

[E_L]

they co-develop and co-promote, but maybe they don't co-book

[Solsen]

Seagen will be responsible for commercializing tisotumab vedotin and Genmab will receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the mid-twenties.